Pharmacological Characterization of a Novel ENaCα siRNA (GSK2225745) With Potential for the Treatment of Cystic Fibrosis

MLA

Kenneth L Clark, et al. “Pharmacological Characterization of a Novel ENaCα SiRNA (GSK2225745) With Potential for the Treatment of Cystic Fibrosis.” Molecular Therapy: Nucleic Acids, vol. 2, no. C, Jan. 2013. EBSCOhost, https://doi.org/10.1038/mtna.2012.57.

APA

Kenneth L Clark, Stephen A Hughes, Pallav Bulsara, Jill Coates, Kitty Moores, Joel Parry, Michael Carr, Ruth J Mayer, Paul Wilson, Chris Gruenloh, Daren Levin, Jill Darton, Wolf-Michael Weber, Katja Sobczak, Deborah R Gill, Stephen C Hyde, Lee A Davies, Ian A Pringle, Stephanie G Sumner-Jones, … Mark R Edbrooke. (2013). Pharmacological Characterization of a Novel ENaCα siRNA (GSK2225745) With Potential for the Treatment of Cystic Fibrosis. Molecular Therapy: Nucleic Acids, 2(C). https://doi.org/10.1038/mtna.2012.57

Chicago

Kenneth L Clark, Stephen A Hughes, Pallav Bulsara, Jill Coates, Kitty Moores, Joel Parry, Michael Carr, et al. 2013. “Pharmacological Characterization of a Novel ENaCα SiRNA (GSK2225745) With Potential for the Treatment of Cystic Fibrosis.” Molecular Therapy: Nucleic Acids 2 (C). doi:10.1038/mtna.2012.57.